Allianz Asset Management GmbH Lowers Stake in QIAGEN N.V. (NYSE:QGEN)

Key Points

• Allianz Asset Management GmbH sold 31,698 shares of Qiagen N.V., reducing its stake by 12.9% in the first quarter, now holding approximately 213,136 shares valued at $8.5 million.
• Wall Street analysts have mixed views on Qiagen, with a range of ratings including a recent downgrade from "strong-buy" to "buy" and several price target increases from various firms.
• Qiagen recently announced a dividend of $0.25 per share, resulting in a yield of 0.52%, with a payout ratio of 62.5% as of the latest quarter.

Allianz Asset Management GmbH reduced its position in QIAGEN N.V. (NYSE:QGEN - Free Report) by 12.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 213,136 shares of the company's stock after selling 31,698 shares during the quarter. Allianz Asset Management GmbH owned about 0.10% of QIAGEN worth $8,518,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Brown Brothers Harriman & Co. acquired a new position in QIAGEN in the 4th quarter valued at $37,000. Tower Research Capital LLC TRC increased its stake in QIAGEN by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after buying an additional 2,204 shares during the period. GAMMA Investing LLC raised its position in QIAGEN by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after acquiring an additional 1,425 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in QIAGEN in the fourth quarter worth $202,000. Finally, GF Fund Management CO. LTD. purchased a new position in QIAGEN in the fourth quarter worth $216,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Robert W. Baird increased their price objective on QIAGEN from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Redburn Atlantic cut QIAGEN from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Barclays assumed coverage on QIAGEN in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective for the company. Bank of America increased their price objective on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Finally, Wall Street Zen lowered QIAGEN from a "strong-buy" rating to a "buy" rating in a report on Saturday. Seven analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, QIAGEN currently has an average rating of "Hold" and a consensus target price of $49.40.

QIAGEN Price Performance

Shares of NYSE:QGEN traded down $0.52 on Wednesday, hitting $50.55. The company had a trading volume of 1,021,075 shares, compared to its average volume of 1,464,010. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. QIAGEN N.V. has a 52-week low of $37.63 and a 52-week high of $51.88. The business has a 50 day moving average of $47.08 and a 200 day moving average of $43.31. The company has a market cap of $11.24 billion, a PE ratio of 126.74, a PEG ratio of 2.59 and a beta of 0.68.

QIAGEN (NYSE:QGEN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. The firm had revenue of $483.46 million during the quarter, compared to analyst estimates of $465.66 million. QIAGEN had a return on equity of 14.61% and a net margin of 4.68%. The business's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.44 earnings per share. As a group, equities analysts anticipate that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.

QIAGEN Dividend Announcement

The business also recently disclosed a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were issued a dividend of $0.25 per share. The ex-dividend date was Wednesday, July 2nd. This represents a dividend yield of 0.52%. QIAGEN's payout ratio is currently 62.50%.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.